528-50-7

Applied Filters:

Keyword:'528-50-7'

Showing 1-3 of 3 results for "528-50-7" within Papers

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma.

Joseph M Parker et al.

BMC pulmonary medicine, 11, 14-14 (2011-03-02)

Interleukin-9 (IL-9)-targeted therapies may offer a novel approach for treating asthmatics. Two randomized placebo-controlled studies were conducted to assess the safety profile and potential efficacy of multiple subcutaneous doses of MEDI-528, a humanized anti-IL-9 monoclonal antibody, in asthmatics. Study 1:

Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.

Chitra Sridar et al.

Drug metabolism and disposition: the biological fate of chemicals, 40(12), 2256-2266 (2012-09-01)

Selegiline, the R-enantiomer of deprenyl, is used in the treatment of Parkinson's disease. Bupropion, an antidepressant, often used to treat patients in conjunction with selegiline, is metabolized primarily by CYP2B6. The effect of selegiline on the enzymatic activity of human

Quantitation of the mRNA levels of Epo and EpoR in various tissues in the ovine fetus.

R Bruce David et al.

Molecular and cellular endocrinology, 188(1-2), 207-218 (2002-03-26)

A partial cDNA of the sheep erythropoietin receptor (EpoR) was obtained and used in real-time PCR to quantitate mRNA levels in placenta, liver and kidney throughout development (term=150 days). This was compared with Epo mRNA levels in the same tissues.

Page 1 of 1